GlaxoSmithKline has formed a vaccine JV with Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. (NIBT), an established China vaccine company. The JV will produce flu vaccines for the China market. It will seek to increase GSK’s presence in emerging markets, which is one of the company’s long-term strategic goals. Also, the JV benefits GSK by using its vaccine adjuvant. More details...

Stock Symbol: (NYSE: GSK)